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Abstract Auranoﬁn is a gold(I)-containing drug in clin-
ical use as an antiarthritic agent. Recent studies showed
that auranoﬁn manifests interesting antiparasitic actions
very likely arising from inhibition of parasitic enzymes
involved in the control of the redox metabolism. Try-
panothione reductase is a key enzyme of Leishmania
infantum polyamine-dependent redox metabolism, and a
validated target for antileishmanial drugs. As trypanothione
reductase contains a dithiol motif at its active site and
gold(I) compounds are known to be highly thiophilic, we
explored whether auranoﬁn might behave as an effective
enzyme inhibitor and as a potential antileishmanial agent.
Notably, enzymatic assays revealed that auranoﬁn causes
indeed a pronounced enzyme inhibition. To gain a deeper
insight into the molecular basis of enzyme inhibition,
crystals of the auranoﬁn-bound enzyme, in the presence of
NADPH, were prepared, and the X-ray crystal structure of
the auranoﬁn–trypanothione reductase–NADPH complex
was solved at 3.5 A ˚ resolution. In spite of the rather low
resolution, these data were of sufﬁcient quality as to
identify the presence of the gold center and of the thiosugar
of auranoﬁn, and to locate them within the overall protein
structure. Gold binds to the two active site cysteine resi-
dues of TR, i.e. Cys52 and Cys57, while the thiosugar
moiety of auranoﬁn binds to the trypanothione binding site;
thus auranoﬁn appears to inhibit TR through a dual
mechanism. Auranoﬁn kills the promastigote stage of
L. infantum at micromolar concentration; these ﬁndings
will contribute to the design of new drugs against
leishmaniasis.
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CTPAu Chloro(triethylphosphine)gold(I)
GR Glutathione reductase
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
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MTT 3-[4.5-dimethylthiazol-2-yl]-2.5-
diphenyltetrazolium bromide
NADH Reduced nicotinamide adenine dinucleotide
NADPH Reduced nicotinamide adenine dinucleotide
phosphate
ROS Reactive oxygen species
TR Trypanothione reductase
TrxR Thioredoxin reductase
TryS Trypanothione synthatase
TS2 Trypanothione disulﬁde
T(SH)2 Trypanothione (N1-N8-bis(glutathionyl)
spermidine
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Leishmania parasites depend on spermidine for growth and
survival. They synthesize polyamines and polyamine pre-
cursors, and also scavenge them from their microenviron-
ment, using speciﬁc transporters. In addition, Leishmania
spp. possess a unique thiol-based, polyamine-based
metabolism, in which trypanothione (N1-N8-bis(gluta-
thionyl)spermidine, T(SH)2) and trypanothione reductase
(TR) replace many of the antioxidant and metabolic
functions of the glutathione/glutathione reductase (GR) and
thioredoxin/thioredoxin reductase (TrxR) systems present
in the host (Colotti and Ilari 2011; Cunningham and Fair-
lamb 1995; Fairlamb et al. 1985).
Consequently, the enzymes involved in spermidine
synthesis and its utilization, i.e. arginase, ornithine decar-
boxylase, S-adenosylmethionine decarboxylase, spermi-
dine synthase, tryparedoxins, tryparedoxin-dependent
peroxidases and, in particular, trypanothione synthetase
(TryS) and TR, are targets for drug development (Colotti
and Ilari 2011).
TryS and TR are necessary for Leishmania survival,
protecting the parasite from oxidative damage and toxic
heavy metals, and allowing the delivery of the reducing
equivalents for DNA synthesis. The known sensitivity of
Leishmania toward reactive oxygen species (ROS) and the
absence of the trypanothione/TR system in the mammalian
host make TryS and TR promising targets for the devel-
opment of parasite-speciﬁc drugs.
TR, as most enzymes involved in the polyamine
metabolism in Leishmania, contains cysteine residues in
the active site, and can be inhibited by metal-containing
compounds. For instance, antimonial drugs, which are used
against leishmaniasis since 1940s (Goodwin and Page
1943), although suffering from high toxicity and increasing
resistance, interfere in vivo with the T(SH)2 metabolism by
inducing rapid efﬂux of intracellular T(SH)2, and inhibit
TR in intact cells (Cunningham and Fairlamb 1995). We
disclosed the molecular mechanism of antimonial inhibi-
tion of TR by structural analysis of reduced TR in complex
with reduced nicotinamide adenine dinucleotide phosphate
(NADPH) and Sb(III) (Baiocco et al. 2009a). This structure
revealed that the two redox-active catalytic cysteine resi-
dues (Cys52 and Cys57), one threonine residue (Thr335)
and His461’ of the twofold symmetry related subunit in the
dimer are engaged in complex formation with Sb(III).
Other metal compounds, such as silver, palladium and
platinum derivatives, were reported to inhibit TR (Baiocco
et al. 2011; Bonse et al. 2000; Otero et al. 2006).
Auranoﬁn (AF) is a gold complex largely used in the
clinics as an antiarthritic drug. It consists of a gold(I) center
linearly coordinated to triethylphosphine and to 3,4,5
triacetyloxy-6-(acetyloxymethyl)oxane-2-thiolate, a thio-
sugar (Fig. 1). Detachment of the latter results into drug
activation. Quite recently, a few studies revealed that
auranoﬁn might be conveniently employed for a number of
different therapeutic indications (Fonteh et al. 2010; Kast
2010; Kean and Kean 2008; Navarro et al. 2010; Prast-
Nielsen et al. 2010). In particular, it was shown that the
gold(I) center of AF, being markedly thiophilic, manifests
a high afﬁnity for dithiol motifs, often present in the active
site of some crucial parasitic enzymes. In view of this
property it was proposed that auranoﬁn might be tested as
an antiparasitic agent.
Since AF induces strong inhibition of parasite growth
for Plasmodium falciparum and for Schistosoma mansoni
through the inhibition of thiol-dependent redox enzymes
such as thioredoxin reductase and thioredoxin glutathione
reductase (Angelucci et al. 2009; Kuntz et al. 2007; San-
nella et al. 2008), we decided to explore whether AF might
be used as an antileishmanial agent, in in vitro tests of
growth inhibition of promastigotes from L. infantum and
L. major species.
To corroborate these hypotheses, auranoﬁn was chal-
lenged in vitro against trypanothione reductase, an impor-
tant target of Leishmania, essential for trypanosomatids, to
test its ability of inhibiting the enzyme. We also obtained
crystal reduced TR from L. infantum in complex with
NADPH and AF, thus demonstrating the mechanism of TR
inhibition by gold derivatives.
In addition, since compounds such as gold(I) triphenyl-
phosphine have a potent antiproliferative effect on Leish-
mania spp. and Trypanosoma cruzi, due to the reduced
nicotinamide adenine dinucleotide (NADH) fumarate
Fig. 1 a Chemical structure of auranoﬁn (AF); b chemical structure
of Chloro(triethylphosphine)gold(I) (CTPAu)
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123reductase inhibition (Vieites et al. 2009), we measured the
ability of Chloro(triethylphosphine)gold(I) (CTPAu), i.e. a
very soluble variant of AF (Fig. 1), which lacks the thio-
sugar moiety, to inhibit TR.
Methods
TR inhibition assay
TR activity was measured at 25C in a diode array Hewlett-
Packard HP8452A spectrophotometer as previously
described (Baiocco et al. 2009a). Experiments for calcu-
lation of the Ki values were carried out by varying AF and
CTPAu concentration. In a cuvette, 40 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)
pH 7.5, 50 mM NaCl, 100 lM NADPH, 40 nM TR and the
gold derivatives were allowed to equilibrate for 2 min at
25C immediately prior the addition of trypanothione
disulﬁde (TS2). Assays were initiated by addition of TS2
and the absorbance decrease at 340 nm, which indicates the
oxidation of NADPH, was followed. The concentrations of
NADPH was calculated using the extinction coefﬁcient of
a e = 6,222 M
-1 cm
-1 at 340 nm. Trypanothione disulﬁde
(Bachem) and NADPH (Sigma) were used for the experi-
ments. Auranoﬁn was purchased from Vinci Biochem and
CTPAu from Sigma Chemical Company.
X-ray structure determination
Crystallization of TR from Leishmania infantum was car-
ried out as reported previously (Baiocco et al. 2009b).
Crystals of the native oxidized form of TR were soaked
for 1 h with a stabilizing solution of 2.5 M ammonium
sulfate, 0.1 M Tris pH 8.5 containing 2 mM AF and 5 mM
NADPH. Crystals were cryo-protected in a solution con-
taining 75% v/v of the reservoir solution and 25% v/v of
glycerol.
Single wavelength data set (k = 0.918 A ˚) was collected
at the beamline ID 14-1 at the synchrotron radiation source
ESRF in Grenoble, France, using a CCD detector at a
temperature of 100 K.
ThedatasetwasprocessedwithDENZO(Otwinowskiand
Minor1997)andscaledwithSCALEPACK(Otwinowskiand
Minor1997).ThecrystalsbelongtotheP41spacegroupwith
thefollowingcelldimensions:a = 103.05 A ˚,b = 103.05 A ˚,
c = 191.6 A ˚. Crystal parameters and complete data collec-
tion statistics are given in Table 1.
The structure of L. infantum TR in complex with AF and
NADPH was solved by molecular replacement using as
search model the native TR (pdb code 2JK6) with the
program Molrep (Vagin and Teplyakov 1997). Reﬁnement
was performed using the program REFMAC5 (Murshudov
et al. 1997) and model building was carried out using the
program COOT (Emsley and Cowtan 2004). The ﬁnal Rcrys
for all resolution shells (50–3.5 A ˚), calculated using the
working set reﬂections (22593), is 26.7% and the free
R value, calculated using the test set reﬂections (1291), is
31.9%. The ﬁnal model is a dimer that contains 976 residues
(488 for monomer A and 488 for monomer B), two FAD
molecules, two NADPH molecules, two gold ions, two
chloride ions, two (3,4,5 triacetyloxy-6-(acetyloxymethyl)
oxane-2-thiolate thiosugars, and two sulphate ions (Schu-
ettelkopf and van Aalten 2004). The most favored regions
of the Ramachandran plot contain 92.2% of residues. The
atomic coordinates and structure factors have been depos-
ited in the Protein Data Bank with the PDB code 2YAU.
Parasite strains and promastigote assays
Promastigote stage of L. infantum strain MHOM/TN/80/
IPT1 and L. major strain MHOM/SU/73/5-ASKH were
used in drug susceptibility assays. Promastigotes were
grown in Schneider’s Drosophila medium (SIGMA) con-
taining 10% Fetal Calf Serum (FCS) (GIBCO-BRL) and
2% gentamicine (50 mg/L) (Sigma) at 22C. The effect on
Table 1 Crystal parameters, data collection and reﬁnement statistics
Data collection
Space group P41
Unit cell dimension (A ˚) a = 103.58, b = 103.58,
c = 191.60
Resolution range (A ˚) 50–3.50 (3.63–3.5)
Total reﬂections 164492
Unique reﬂections 25665
Completeness (%) 100 (100)
Rmerge 0.17 (0.50)
Redundancy 6.4 (6.4)
\I/r(I)[ 9.4 (1.9)
Reﬁnement statistics
Resolution range (A ˚) 50.0–3.5 (3.59–3.50)
Free R value (%) 31.9 (41.3)
R value (working set) (%) 26.7 (39.7)
RMS bonds (A ˚) 0.009
RMS angles () 1.24
Ramachandran analysis
Residues in most favoured regions (%) 92.2
Residues in allowed regions (%) 7.1
Outliers (%) 0.7
Values in parentheses are for the highest resolution shell
Rmerge = RhklRi |Ii(hkl) -\I(hkl)[|/RhklRi Ii(hkl) where Ii(hkl) is the
ith observation of the reﬂection (hkl) and \I(hkl)[ is the mean
intensity of the (hkl) reﬂection
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123cell growth was analyzed incubating an initial concentra-
tion of 1 9 10
6 parasites/mL with various concentrations
of the compounds.
Brieﬂy, a 200 lL volume of suspension was seeded in
triplicate in 96-well ﬂat-bottom microtrays and incubated
with different concentration of two gold compounds (AF
and CTPAu): 50, 40, 30, 25, 20, 15, 10, 7.5, 5, 2.5,
1.25 lM. Antimonial compound was used as the reference
anti-Leishmania drug. Each experiment was carried out in
triplicate for each concentration. After 72 h of incubation,
40 lL of MTT (3-[4.5-dimethylthiazol-2-yl]-2.5-diphe-
nyltetrazolium bromide) was added to each well and plates
were further incubated for 2 h. The absorbance at 490 nm
was measured with a 96-well scanner. Two independent
experiments in triplicate were performed. In addition, the
promastigote vitality was followed by microscopic obser-
vation after 72 h. Dose–response curves were recorded and
the 50% inhibitory concentration (IC50) values were
determined by GraphPad Prism 5.
Results
At ﬁrst, we explored whether AF might behave as an
inhibitor of TR. Steady state condition kinetic experiments
were carried out at various concentration of TS2 and
inhibitor. After starting the reaction by the addition of TS2,
the absorbance decrease at 340 nm, which indicates the
oxidation of NADPH, was measured. Although a few tra-
ces (Fig. 2a, b) show a complex behavior, possibly due to
auranoﬁn modiﬁcation, AF has a clear inhibitory effect on
TR. Addition of increasing amount of AF resulted into
remarkable enzyme inhibition, with a Ki value of
155 ± 35 nM, about 10 times lower than Sb(III) (Baiocco
et al. 2009a), in the conditions tested (Fig. 2). CTPAu has a
even higher inhibitory activity on TR, with a Ki of
18 ± 7 nM (Fig. 2).
To unveil the structural basis of enzyme inhibition, we
tried to prepare crystals of the AF-inhibited enzyme that
could be suitable for X-ray diffraction analysis. Several
attempts were made based on co-crystallization, but all of
these failed, since no crystals of crystallographic quality
were obtained. Crystals of reduced TR in complex with
NADPH and AF of reasonable crystallographic quality
were in turn obtained by soaking crystals of oxidized TR
for 1 h with a stabilizing solution of 2.5 M ammonium
sulfate, 0.1 M Tris pH 8.5 containing 2 mM AF and 5 mM
NADPH. These crystals were used to solve the structure
TR in complex with AF at 3.5 A ˚ resolution.
In spite of the fact that the resolution is rather low,
diffraction data were sufﬁcient to delineate the overall
protein structure, which is practically superposable (RMSD
about 0.5 A ˚) to those obtained for the Sb(III)-bound and
the silver-bound TR structures (Baiocco et al. 2009a, 2011)
(Fig. 3). A very clear electron density in the Fo-Fc map
was found in both subunits, accounting for the presence of
gold ions nearby the catalytic site, namely Cys52, Cys57
and His461’ with an occupancy of 40% for both subunits
(Fig. 4a).
In addition, the inspection of the electronic density map
allowed us to identify the thiosugar moiety of AF in the
active site of TR with an occupancy of 70% (Fig. 4b). The
Fo-Fc electronic density map contoured at 3.0 A ˚ indicates
the presence of an additional conformation with low
occupancy.
As shown in the Fig. 4a, Au(I) is coordinated by three
ligands. The two cysteine residues of the active site (Cys52
Fig. 3 X-ray structure of the Au(I)-TR complex A. Overall structure.
The two subunits in the asymmetric unit are colored in red and in
blue, respectively. The trypanothione binding cavities are indicated
by arrows and the thiosugar moiety is indicated in CPK. The picture
is generated in PyMol (DeLano 2008)
Fig. 2 Inhibition of TR by AF and CTPAu. a–d Oxidation kinetics of
NADPH (100 lM) in the presence of 40 nM TR and of different
concentrations of AF and TS2, measured at 340 nm. [TS2] a 50 lM;
b 100 lM; c 200 lM; d 400 lM. [AF] traces in a 0, 20, 40, 100, 120,
250, 500 nM, 1, 5 lM; traces in b 0, 50, 120, 200, 500 nM, 1, 2,
10 lM; traces in c 0, 50, 100, 200, 500 nM, 1, 2, 10 lM; traces in d:
0, 50, 100, 200, 400 nM, 1, 2, 5, 10 lM. e Lineweaver–Burk plot and
f Dixon plot of TR inhibition by auranoﬁn. e ﬁlled squares [AF] = 0;
open squares [AF] = 50 nM; ﬁlled circles [AF] = 100 nM; open
circles [AF] = 200 nM. f ﬁlled squares [TS2] = 50 lM; open
squares [TS2]=100 lM; ﬁlled circles [TS2] = 200 lM; open circles
[TS2] = 400 lM. g Lineweaver–Burk plot and h Dixon plot of TR
inhibition by CTPAu. g ﬁlled squares [CTPAu] = 0; open squares
[CTPAu] = 10 nM; ﬁlled circles [CTPAu] = 25 nM; open circles
[CTPAu] = 40 nM; ﬁlled triangles [CTPAu] = 60 nM; open trian-
gles [CTPAu] = 100 lM. h open squares [TS2] = 100 lM; open
circles [TS2]=200 lM
b
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SGCys52–Au = 2.1 A ˚ and SGCys57–Au = 2.1 A ˚, respec-
tively. The third ligand is a chloride ion, placed at a dis-
tance of 2.5 A ˚ from Au(I). Thus, in the auranoﬁn–TR
complex the gold ion displays a planar-trigonal coordina-
tion, where the ligands are the two cysteine residues and a
chloride ion, one of the principal coordination geometries
of the d
10 closed-shell-conﬁguration Au(I) (Shaw 1999).
The 3,4,5-triacetyloxy-6-(acetyloxymethyl)oxane-2-
thiolate thiosugar is bound at the trypanothione binding
site, and forms contacts with the chloride ion and with two
important residues of TR, His4610 and Glu4660, belonging
to the second subunit of the dimer, which activate Cys52
similarly to serine and cysteine proteases during trypano-
thione reduction (Fig. 4b). The distance between the sul-
phur atom of the thiosugar and the chloride is 3.1 A ˚, while
the acetate groups of the thiosugar are at distances of about
3A ˚ from His4610, Glu4660 and Glu4670. In particular, the
oxygen atoms of the acetate groups are 2.9 A ˚ away from
the nitrogen NE2 of His4610, 3.1 A ˚ apart from the carboxyl
group of Glu4660, and at 3.3 A ˚ from the carboxyl group of
Glu467’. Therefore, AF blocks the two cysteine residues of
the active site, and does not allow binding of trypanothione
to His4610, belonging to the catalytic triad of TR, and to
Glu4660, which stabilizes the His4610 positive charge
during the redox reaction catalysed by TR.
The possible use of AF as antileishmanial drug was
tested by promastigote growth inhibition assays.
Both AF and CTPAu induced a dose-dependent anti-
proliferative effect on promastigotes, the extracellular
Leishmania stage of both L. infantum and L. major species.
A dose of 50 lM of either gold compounds induced 100%
promastigote mortality, whereas concentrations \40 lM
determined a leishmanistatic activity, with different rates
of inhibition activity of two Leishmania species. At these
sub-lethal concentrations, parasites showed motility inhi-
bition and body swelling, not present in control cells.
Lower concentrations, B2.5 lM, did not affect either
promastigote growth or morphology. The IC50 values
deduced from the dose–response curve are different for the
two compounds (Table 2). AF produced a higher leish-
manistatic activity than CTPAu against both Leishmania
species. Indeed, the auranoﬁn IC50 was 9.68 ± 1.02 lM
for L. infantum and 15.66 ± 1.24 lM for L. major,
whereas the CTPAu IC50 showed slightly higher values, i.e.
16.59 ± 1.03 lM for L. infantum and 17.48 ± 1.02 lM
for L. major.
Discussion
The experiments presented in the present work show that
auranoﬁn, a drug used against rheumatoid arthritis, is able
to inhibit with a dual mechanism the trypanothione
reductase, a key enzymes of the polyamine metabolism in
Leishmania, thereby killing the Leishmania parasites.
The available treatments for leishmaniasis are far from
ideal. The traditional ﬁrst-line treatment relies on penta-
valent antimonials. Amphotericin B, the aromatic diami-
dine pentamidine and, more recently, miltefosine, are often
effective, though they also have severe side effects.
With the exception of antimonials, the use of metal-
containing drugs as antileishmanial agents has not been
deeply explored up to now, although the emergence of
Fig. 4 a Au(I) binding site. The gold and the chloride ions are
indicated in orange and green, respectively. The anomalous differ-
ence Fourier map for data collected at the gold peak wavelength is
shown at a 5r contour level in green. b Trypanothione binding site.
The Cys52, Cys57, Thr335, His4610, Glu4660 residues, the FAD
molecule and the thiosugar moiety are represented as sticks. The
pictures have been generated in PyMol (DeLano 2008)
Table 2 Activity of auranoﬁn and CTPAu against Leishmania
parasites
Compounds L. infantum L. major
Auranoﬁn 9.68 ± 1.02 15.66 ± 1.24
CTPAu 16.59 ± 1.03 17.48 ± 1.02
Results are expressed as IC50 (lM) ± standard error
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123drug-resistant strains of Leishmania warrants screening of
new compounds and rational drug design.
Metals are often considered not selective. However, a
few studies show promising results against the parasite. For
example, zinc sulfate was tested clinically against cutane-
ous leishmaniasis, with cure rates [96.0% (Minodier and
Parola 2007). Platinum-based DNA intercalators inhibit
growth of Leishmania parasites (Lowe et al. 1999; Visbal
et al. 2008), also displaying inhibitory activity versus
metabolically important enzymes. A gold(I)-based com-
plex with the bioactive coligand pyridine-2-thiol N-oxide
shows inhibition of NADH fumarate reductase, a kineto-
plastid parasite-speciﬁc enzyme absent in the host (Visbal
et al., 2008), while gold(III) derivatives as [Au(dppz)2]Cl3
and Au(III) cyclometallated complexes are DNA interca-
lators with antileishmanial activity, the latter inhibiting
different cysteine proteases in Trypanosoma and Leish-
mania (Fricker et al. 2008; Navarro et al. 2007).
These results prompted us to study the possibility of
using AF, a gold(I)-containing drug, with known pharma-
cokinetics and pharmacodynamics, against leishmaniasis.
Auranoﬁn (Ridaura), gold sodium thiomalate and auro-
thioglucose (Solganal) are gold-containing chemicals used
in treating rheumatoid arthritis. In patients with inﬂam-
matory arthritis, such as adult and juvenile rheumatoid
arthritis, gold salts decrease the inﬂammation of the joint
lining and also prevent the inﬂammation from destroying
the bone and cartilage surrounding the joint. Because they
prevent destruction of joints (in contrast to antiinﬂamma-
tory drugs that just treat symptoms and signs of arthritis but
do not prevent the destruction) AF is known as a disease-
modifying antirheumatic drug (DMARD) (Rau 2005).
Chrysotherapy is also considered for cancer (Marzano et al.
2007; Shaw 1999).
The mechanism of action of AF is not fully known; gold
is taken up by macrophages, which results in inhibition of
phagocytosis and lysosomal membrane stabilization; other
actions observed are decreased serum rheumatoid factor
and alterations in immunoglobulins. Additionally, com-
plement activation is decreased, prostaglandin synthesis is
inhibited, and lysosomal enzyme activity is decreased
(Bondeson 1997; Haynes et al. 1988).
In addition, AF and other gold-containing drugs are
strong inhibitors of protozoan thioredoxin glutathione
reductase and of mammalian thioredoxin reductases
(Gromer et al. 1998; Kuntz et al. 2007). Notably, inhibition
of these reductases is associated with important modiﬁca-
tions of the intracellular redox balance and, in particular,
with induction of severe oxidative stress and relevant
cytotoxic effects in vitro (Lu et al. 2007; Yoo et al. 2006).
Since Leishmania effectively avoids the humoral branch
of the host immune system by infecting preferentially the
macrophage as amastigote, the preferential uptake of AF by
the macrophages is of particular importance for treatment
of leishmaniases, and should make the drug more effective
and speciﬁc against the parasite.
AF inhibits TR from L. infantum with a Ki of
155 ± 35 nM, while the inhibition constant measured for
Sb(III) is 1.5 lM: another gold(I) derivative, CTPAu, a
very soluble variant of AF, lacking its thiosugar moiety,
inhibits TR with a Ki of 18 ± 7 nM. Therefore, Au(I)-
containing drugs are more effective than antimony in vitro.
Recently, inhibition constants for Ag(0) and Ag(I) of 500
and 50 nM, respectively, were measured on TR (Baiocco
et al. 2011). Therefore, Au(I)-containing compounds are
very effective TR inhibitors.
The structural analysis of the crystal of reduced
L. infantum TR in complex with NADPH and AF, solved at
3.5 A ˚ resolution, demonstrates that the mechanism of
inhibition is only partly similar to that of Sb(III). In fact the
structure inspection clearly show that upon TR reduction
by NADPH, Au(I) binds to the two cysteines Cys52 and
Cys57 with a planar triangular coordination involving also
a chloride ion, while both Sb(III) and silver bind the three
residues of the catalytic triad (Cys52, Cys57 and His4610)
of the enzyme.
In addition, although the relatively low resolution of the
structure impairs a deeper analysis, the 3,4,5-triacetyloxy-
6-(acetyloxymethyl)oxane-2-thiolate thiosugar of AF
clearly occupies the trypanothione binding site, thus
impairing substrate binding and engaging in hydrogen bond
interactions both His4610 and Glu4660, that are involved in
Cys52 activation during catalysis (Baiocco et al. 2009a;
Karplus and Schulz 1989). AF therefore inhibits TR with a
dual mechanism, i.e. by blocking both binding and reduc-
tion of oxidized trypanothione by TR.
These results are conﬁrmed by in vitro experiments on
L. infantum promastigotes, which showed that AF is able to
kill the parasite at micromolar concentrations.
For these reasons, the authors believe that the use of
gold-containing compounds represents a reasonable
approach for the optimization of therapeutic strategies
against leishmaniasis.
Conclusions
In the structures of TR in complex with NADPH and AF, as
for those with Sb(III) or silver (Baiocco et al. 2009a, 2011),
the metal ion is tightly bound to two cysteine groups in the
active site of the enzyme, thereby disallowing the hydride
transfer from the protein to the trypanothione. In addition,
the thiosugar of auranoﬁn contributes to TR inhibition by
occupying the trypanothione binding site of TR.
This ﬁnding, and the works reporting that, in addition to
gold derivatives, also silver, palladium and platinum
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2011; Bonse et al. 2000; Otero et al. 2006), suggest that
thiophilic metals that are Lewis soft acids, more generally,
may serve as strong inhibitors of TR and may result in
potential interest as antileishmanial agents.
The structural studies were independently supported by
enzyme inhibition data for AF and CTPAu.
Such metal-dependent inhibition of thiol reductases
opens the way to combined metal therapy of leishmaniasis.
In view of these results we can state that AF behaves as a
relatively strong inhibitor of TR and is endowed of antile-
ishmanial activity in the micromolar range of concentration.
Studies are in progress to evaluate comparative enzyme
inhibition by a series of structurally different gold
complexes.
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